Promising effects of parasite-derived compounds on tumor regression: a systematic review of in vitro and in vivo studies

Asghari, Ali; Nourmohammadi, Hassan; Majidiani, Hamidreza; Shariatzadeh, Seyyed Ali; Anvari, Davood; Shamsinia, Sadegh; Ghasemi, Ezatollah; Shams, Morteza; Basati, Gholam

doi:10.1007/s11356-021-17090-5

Cited by 7 publications

(3 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, we have explored the role of parasitic diseases as cancer inducers or promoters. However, in recent years, 13 parasitic agents, some of which are familiar to veterinarians (such as Toxoplasma gondii, Echinococcus granulosus, Trichinella spiralis, and Toxocara canis), have been investigated as mediators of anti-tumor responses, further complicating an already complex picture [383]. Several anti-tumor mechanisms, including the sharing of common antigens and the enhancement of active tumor surveillance via antibody-dependent cellular cytotoxicity (ADCC), have been proposed and detailed extensively elsewhere [384][385][386].…”

Section: Antitumor Activitymentioning

confidence: 99%

Cancerogenic parasites in veterinary medicine: a narrative literature review

Fonti

Parisi

Mancianti

et al. 2023

Infect Agents Cancer

View full text Add to dashboard Cite

Parasite infection is one of the many environmental factors that can significantly contribute to carcinogenesis and is already known to be associated with a variety of malignancies in both human and veterinary medicine. However, the actual number of cancerogenic parasites and their relationship to tumor development is far from being fully understood, especially in veterinary medicine. Thus, the aim of this review is to investigate parasite-related cancers in domestic and wild animals and their burden in veterinary oncology. Spontaneous neoplasia with ascertained or putative parasite etiology in domestic and wild animals will be reviewed, and the multifarious mechanisms of protozoan and metazoan cancer induction will be discussed.

show abstract

Section: Antitumor Activitymentioning

confidence: 99%

Cancerogenic parasites in veterinary medicine: a narrative literature review

Fonti

Parisi

Mancianti

et al. 2023

Infect Agents Cancer

View full text Add to dashboard Cite

show abstract

“…To harness the anticancer potential of helminths effectively, it is imperative that researchers fully comprehend the details of immunomodulation. Helminths exert their anticancer effects by modulating the immune system and directly targeting cancer cells (Reens et al, 2021;Asghari et al, 2022;Lee et al, 2023). Helminth's capabilities could be harnessed to enhance or complement anticancer therapies.…”

Section: Anticancer Propertiesmentioning

confidence: 99%

“…Historically, most of them are responsible for human diseases, but scientific evidence in recent years indicates that they may also provide therapeutic benefits, especially for cancer treatment (Oikonomopoulou et al, 2014;Scholte et al, 2018). Parasitic helminths such as Trichinella spiralis (T. spiralis), Echinococcus granulosus (E. granulosus), Toxocara canis (T. canis), and Taenia solium (T. solium) have offered a novel perspective on cancer treatment due to their antigen similarity with cancer (Ditgen et al, 2014;Asghari et al, 2022). It has been discovered that some of these molecules can modulate the immune system at a fundamental level, which is a critical factor in the development and progression of cancer (Callejas et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Using Helminths to Fight Cancer: An Innovative Approach

Ameli,

Masoumi,

Kerachi

et al. 2023

WVJ

View full text Add to dashboard Cite

As an alternative treatment in cancer therapy, there has been a growing interest in using helminths, such as Trichinella spiralis (T. spiralis), Echinococcus granulosus (E. granulosus), Toxocara canis (T. canis), and Taenia solium (T. solium). This study aimed to investigate the antigens and mechanisms that contribute to the anticancer properties of helminths, providing insights into how helminths may be used as a new and innovative treatment modality for cancer. The current review analyzed preclinical and clinical studies published between 2000 and 2023. The present study sought to obtain information on helminths, such as E. granulosus, T. spiralis, T. canis, and T. solium, to treat cancers of the breast, pancreas, melanoma, and leukemia by exploring databases, such as PubMed, Google Scholar, and Scopus. Studies focusing on helminth therapy against particular cancer types for in vitro and animal models were included. Several studies have shown the possibility of inhibiting breast, colon, melanoma, and leukemia tumor growth, inducing apoptosis, and modulating the tumor microenvironment with E. granulosus, T. spiralis, T. canis, and T. solium based on in vitro and animal models studies. Some studies have indicated that helminth therapy can improve survival rates, reduce tumor growth, and stimulate the immune system in cancer patients. A potential improvement in treatment outcomes can be used for combination therapies, such as antigen selection, immune profiling, and individualized approaches based on helminth therapy. Helminth therapy is an additional option for cancer treatment, emphasizing T. spiralis, E. granulosus, T. canis, and T. solium. These helminth antigens could modulate immune responses and directly cause cytotoxicity in cancer cells.

show abstract